...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus
【24h】

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus

机译：依普列净改善2型糖尿病患者的血糖控制并降低体内脂肪

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Ipragliflozin, a sodium-glucose transporter 2 inhibitor, was administered to patients with type 2 diabetes mellitus for 24 weeks to evaluate its effect on glycemic control and body composition.Methods: This was an investigator-initiated multicenter prospective intervention study in which ipragliflozin (50 mg) was administered once daily and glycemic control, blood pressure, body weight (BW), body composition (measured by a biological impedance method), the lipid profile, and adverse events were evaluated after 4, 12, and 24 weeks of treatment.Results: Efficacy and safety up to 24 weeks of ipragliflozin therapy were analyzed in 367 patients and 451 patients, respectively. Hemoglobin A1c decreased significantly from 8.07% at the start of ipragliflozin therapy to 7.26% in week 24 (P < 0.001). Fasting and postprandial blood glucose levels were significantly reduced by ipragliflozin. In week 24, there were significant decreases from baseline in BW (-2.6 kg), waist circumference (-2.9 cm), and body fat mass (-1.9 kg) (P < 0.001). The body water mass and mineral mass were decreased significantly by 0.5 and by 0.1 kg, respectively (P < 0.001), whereas the protein mass did not change significantly. Intracellular water mass did not change significantly, whereas extracellular water mass showed a significant decrease of 0.5 kg (P < 0.001). Muscle mass did not change in the upper and lower limbs, but that of the trunk decreased significantly (P < 0.001). There was a significant decrease in the fasting triglyceride level and a significant increase in fasting high-density lipoprotein cholesterol level, while low-density lipoprotein cholesterol was unchanged. Adverse events occurred in 23.5% of the patients, with a high frequency of genital infections, such as vulvovaginal candidiasis (3.1%) and genital pruritus (1.8%). Adverse drug reactions were noted in 13.7% of the patients.Conclusions: Administration of ipragliflozin for 24 weeks improved glycemic control and decreased BW. Reduction of body fat accounted for more than 70% of the total weight loss and reduction of extracellular water accounted for about 20%.J Clin Med Res. 2017;9(7):586-595doi: https://doi.org/10.14740/jocmr3038w
机译：背景：对2型糖尿病患者给予伊格列净，一种钠-葡萄糖转运蛋白2抑制剂，持续24周，以评估其对血糖控制和身体成分的影响。每天一次（50 mg），并在服用4、12和24周后评估血糖控制，血压，体重（BW），身体组成（通过生物阻抗法测量），脂质状况和不良事件。结果：分别对367例患者和451例患者进行了ipragliflozin治疗长达24周的疗效和安全性分析。血红蛋白A1c从伊格列净治疗开始时的8.07％显着降低至第24周的7.26％（P <0.001）。依普列净可显着降低空腹和餐后血糖水平。在第24周，体重（-2.6千克），腰围（-2.9厘米）和体脂肪量（-1.9千克）较基线显着下降（P <0.001）。人体的水和矿物质的质量分别显着下降了0.5和0.1 kg（P <0.001），而蛋白质的质量没有显着变化。细胞内水量没有显着变化，而细胞外水量显示明显减少了0.5 kg（P <0.001）。上肢和下肢的肌肉质量没有变化，但躯干的肌肉质量显着下降（P <0.001）。空腹甘油三酯水平显着降低，而高密度脂蛋白胆固醇水平空腹显着增加，而低密度脂蛋白胆固醇水平未改变。不良事件发生在23.5％的患者中，生殖器官感染的发生率很高，例如念珠菌性外阴阴道炎（3.1％）和生殖器瘙痒（1.8％）。 13.7％的患者出现药物不良反应。结论：依普列净治疗24周改善了血糖控制，降低了BW。体内脂肪的减少占总体重减轻的70％以上，细胞外水的减少约占总体重的20％。 2017; 9（7）：586-595doi：https://doi.org/10.14740/jocmr3038w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号